Boehringer Ingelheim posts 8.3% growth in first half of 2009

Ingelvac Circoflex, a pig vaccine manufactured by the company, was the key driver behind this performance.

Boehringer Ingelheim, the Germany-based pharmaceutical company, posted 8.3% growth for the first six months of 2009, compared with the same period last year.

The company recorded net sales of  US$9,018 million compared with US$7,795 million during the first six months of the previous year. The strong results were mainly due to expansion in the areas of animal health, which witnessed rising sale of vaccines, and human pharmaceuticals, which saw new prescription medicines developed by the company gaining a stronghold in the market.

The animal health division grew 27.9% with sales of US$403 million.

Page 1 of 54
Next Page